News & Events

Next Generation CAR & T Cell Therapies 2021
June 22, 2021

12:00pm ET

More Event Information>

Umoja Biopharma Closes an Oversubscribed $210 Million Series B Financing to Expand Integrated Immunotherapy Platforms and Advance Programs to the Clinic
June 15, 2021

Seattle, Wash., June 15, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the completion of an oversubscribed $210 million Series B financing.

READ MORE >

Umoja Biopharma Announces Appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer
June 8, 2021

Seattle, WA, June 8, 2021– Umoja Biopharma, a leading oncology company leveraging its proprietary, integrated technologies to reprogram immune cells directly in the human body to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer.

READ MORE >

International Society for Cell & Gene Therapy
May 25, 2021

12:30pm ET

More Event Information>

Umoja Biopharma Announces Appointment of Dr. Irena Melnikova as Chief Financial Officer
May 18, 2021

Umoja Biopharma, a biotechnology company pioneering an integrated, in vivo immunotherapy platform, today announced the appointment of Irena Melnikova, Ph.D., as Chief Financial Officer.

READ MORE >

We are led by a world class team that operates on a foundation of respect for the contributions of everyone on the Umoja team.